Myriad Genetics (MYGN) Q2 FY26 earnings call

Myriad Genetics reported a challenging Q2 FY26, with revenue and average revenue per test declining significantly due to elevated payer friction and a write-off of aged receivables. Despite strong volume growth in cancer care and mental health, the company lowered its full-year revenue guidance and suspended EBITDA guidance. Management is implementing strategic initiatives, including a comprehensive organizational review and enhanced reimbursement strategies, aiming for strengthened growth and profitability from 2027 onwards.